CN104220097B - 促甲状腺激素组合物 - Google Patents

促甲状腺激素组合物 Download PDF

Info

Publication number
CN104220097B
CN104220097B CN201280069717.0A CN201280069717A CN104220097B CN 104220097 B CN104220097 B CN 104220097B CN 201280069717 A CN201280069717 A CN 201280069717A CN 104220097 B CN104220097 B CN 104220097B
Authority
CN
China
Prior art keywords
tsh
rhtsh
peg
pegylated
pegylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280069717.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104220097A (zh
Inventor
C·潘
S·帕克
H·邱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN104220097A publication Critical patent/CN104220097A/zh
Application granted granted Critical
Publication of CN104220097B publication Critical patent/CN104220097B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201280069717.0A 2011-12-19 2012-12-04 促甲状腺激素组合物 Active CN104220097B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577412P 2011-12-19 2011-12-19
US61/577,412 2011-12-19
PCT/US2012/067705 WO2013095905A1 (en) 2011-12-19 2012-12-04 Thyroid stimulating hormone compositions

Publications (2)

Publication Number Publication Date
CN104220097A CN104220097A (zh) 2014-12-17
CN104220097B true CN104220097B (zh) 2019-08-09

Family

ID=47520247

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280069717.0A Active CN104220097B (zh) 2011-12-19 2012-12-04 促甲状腺激素组合物

Country Status (7)

Country Link
US (4) US20140357846A1 (enExample)
EP (1) EP2793948B1 (enExample)
JP (1) JP6255348B2 (enExample)
KR (1) KR102071731B1 (enExample)
CN (1) CN104220097B (enExample)
BR (1) BR112014014868B1 (enExample)
WO (1) WO2013095905A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101687270B1 (ko) 2013-10-29 2016-12-19 한국 한의학 연구원 상륙 추출물 또는 이의 분획물을 함유하는 갑상선 질환의 예방 또는 치료용 조성물
KR101794289B1 (ko) * 2015-11-05 2017-11-06 주식회사 프로젠 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 정제 방법
MA45473A (fr) * 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0228604A3 (en) 1985-12-11 1988-10-12 Sloan-Kettering Institute For Cancer Research Isolation of a gene encoding human thyrotropin beta subunit
NZ513077A (en) * 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
MXPA05006688A (es) * 2002-12-19 2006-02-22 Nektar Therapeutics Al Corp Conjugados de polimero con una variante de cianovirina.
CA2547631A1 (en) * 2003-12-05 2005-06-23 Zymogenetics, Inc. Methods for treating inflammation using thyroid stimulating hormone
JP5216580B2 (ja) * 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
US20090208480A1 (en) * 2006-08-04 2009-08-20 Yue Huang Long half-life recombinant butyrylcholinesterase
PL2063909T3 (pl) * 2006-09-19 2013-05-31 Genzyme Corp Formulacje do terapeutycznego podawania hormonu tyreotropowego (TSH)
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
EP2569331A1 (en) * 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
IT1404011B1 (it) * 2010-12-03 2013-11-08 Uni Degli Studi Magna Graecia Di Catanzaro Nanovettore coniugato con tsh per il trattamento del cancro della tiroide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds

Also Published As

Publication number Publication date
JP2015502363A (ja) 2015-01-22
US20140357846A1 (en) 2014-12-04
US20170065725A1 (en) 2017-03-09
HK1198424A1 (en) 2015-04-24
US20230126645A1 (en) 2023-04-27
KR102071731B1 (ko) 2020-01-30
WO2013095905A1 (en) 2013-06-27
BR112014014868B1 (pt) 2022-12-27
JP6255348B2 (ja) 2017-12-27
EP2793948B1 (en) 2022-03-23
EP2793948A1 (en) 2014-10-29
BR112014014868A2 (pt) 2020-10-27
KR20140103165A (ko) 2014-08-25
CN104220097A (zh) 2014-12-17
US20180326082A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
CN105148287B (zh) Fviii的位点定向修饰
CN101547935B (zh) 干扰素α突变体及其聚乙二醇衍生物
US20230126645A1 (en) Thyroid stimulating hormone compositions
Wu et al. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone
CN102234310B (zh) 一种聚乙二醇修饰蛋白的分离纯化方法
JPH06506218A (ja) ポリペプチドのｐｅｇ化
WO2012109975A1 (zh) 聚乙二醇化犬源尿酸氧化酶类似物蛋白及其制备方法和用途
TWI281864B (en) N-terminally monopegylated human growth hormone conjugates and process for their preparation
US12441766B2 (en) Artificial recombinant protein for improving performance of active protein or polypeptide and use thereof
Qiu et al. Site-specific PEGylation of human thyroid stimulating hormone to prolong duration of action
CN111194223B (zh) 与白蛋白具有较佳结合亲和力的药物分子
ES2386575T3 (es) Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
CN101880326B (zh) 干扰素‑β复合物
HK1198424B (en) Thyroid stimulating hormone compositions
CN104447981B (zh) 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物
JP6367952B2 (ja) エリスロポエチンおよび分枝ポリマー構造を含む複合体
Schrimsher et al. PEGylation of Proteins: A Structural Approach
KR20180087864A (ko) 신규 엑세나타이드 변이체-고분자 복합체
HK1226754A1 (en) Site-directed modification of fviii

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant